IRVINE, Calif. and TEDDINGTON, England, Feb. 7, 2013 /PRNewswire/ -- ChromaDex® Corporation (OTCQB: CDXC) ("ChromaDex") and LGC Standards announced today that they have signed an agreement for ChromaDex to distribute a new range of reference standards called LoGiCal®, which will focus on the forensic and clinical sectors and their line of pharmaceutical impurities standards. ChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. LGC Standards is a provider of products and services to improve measurement and quality control within the laboratory and is a major division of U.K.-based LGC, whose LGC Science & Technology Division acts as the U.K. National Measurement Institute for chemical and bioanalytical measurements.
LoGiCal®, as a new product range focusing on the needs of forensic and clinical laboratories, will provide access to a wide variety of reference materials, including drugs of abuse, prescription drugs and drug metabolites. A segment of this product line is ISO Guide 34 certified, which ensures that all methods a manufacturer uses to certify their standards are validated and proven to be accurate, a new addition to the ChromaDex portfolio. This will add to ChromaDex's extensive current catalog that contains over 3,000 phytochemicals and 470 botanical reference materials that serve a wide variety of markets such as food & beverage, pharmaceutical, cosmeceutical, research organizations and governmental groups.
Frank Jaksch, CEO and co-founder of ChromaDex commented, "By adding the LoGiCal® reference standards to our portfolio of offerings, we further add to our ability to be a one-stop shop for our customers."
Dr. Keith Williams, Product Manager and Key Account Manager at LGC Standards, said, "We are delighted that ChromaDex is incorporating LoGiCal® products into their portfolio. The availability of these high quality reference materials will allow U.S. laboratories to meet their compliance needs."
ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products includes patented pTeroPure® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. The company has also launched ProC3G, a natural black rice extract containing 40% cyanidin-3-glucoside, NutraGAC, a Gac fruit powder rich in lycopene and beta-carotene and pteroberry, an organic blend of pterostilbene, cranberry and blueberry. ChromaDex is also in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property.
About LGC Standards:
LGC Standards (www.lgcstandards.com) provides products and services to improve measurement and quality control within the laboratory, and is part of LGC, whose LGC Science & Technology Division acts as the UK National Measurement Institute for chemical and bioanalytical measurements. LGC Standards supplies over 100,000 products, including reference materials, pharmaceutical impurity reference standards (produced under ISO Guide 34 accreditation), biological standards and reagents, and proficiency testing. LGC Standards is headquartered in Teddington, Middlesex, UK. Its global centre for excellence in proficiency testing is located in Bury (Greater Manchester). LGC Standards has offices in France, Germany, Italy, Poland, Spain, Sweden, China, Russia, United Arab Emirates and the UK, a joint venture presence in India, and representatives in Brazil, Bulgaria, Czech Republic, Finland, Hungary, Ireland, the Netherlands, Romania, Turkey and the US.
LGC (www.lgcgroup.com) is the international science-based company and market leader in analytical, forensic, biotechnology and diagnostic services, as well as diagnostic products, proficiency testing and reference standards. LGC operates in a variety of international markets which underpin the safety, health and security of the public and the regulation of industry, for both public and private sector clients. LGC has four divisions - LGC Forensics, LGC Genomics, LGC Standards and LGC Science & Technology. The latter includes specialist laboratories delivering contracts for the Department for Business, Innovation and Skills (BIS) and supports LGC's designated role as the UK's National Measurement Institute for chemical and bioanalytical measurement.
Our operations are extensively accredited to international quality standards such as ISO/IEC 17025. With headquarters in Teddington, South West London, the LGC Group employs over 1,600 staff in 36 laboratories and centres globally. Privatised in 1996 and now majority-owned by funds managed by Bridgepoint, LGC was founded 170 years ago as the Laboratory of the Government Chemist - a statutory function maintained by LGC today.
Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
ChromaDex Investor Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
Alex Partners, LLC
Scott Wilfong, President
Laura Carney, Executive Assistant
SOURCE ChromaDex Corporation